Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Rubella

Rubella

Subtypes of Rubella

Congenital Rubella Syndrome 3

6 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Rubella

27 trials tracked for Rubella: 23 in phase 3 or 4 and 10 with published results. The most-cited published study has 38 citations.

27Trials tracked
23Phase 3 & 4
0Recruiting
10With published results
Phase distribution
Phase 4 3 Phase 3 20 Phase 2 4
  1. Phase 3 Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older Completed · 38 cited
  2. Phase 3 Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038) Completed · 30 cited
  3. Phase 3 Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age Completed · 20 cited
  4. Phase 3 Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM Completed · 19 cited
  5. Phase 3 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life Completed · 14 cited
  6. Phase 3 Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035) Completed · 13 cited
Show 21 more trials
  1. Phase 3 ProQuad® Intramuscular vs Subcutaneous Completed · 10 cited
  2. Phase 3 Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children Completed · 10 cited
  3. Phase 3 Safety Study of ProQuad® rHA in Infants (V221-037) Completed · 9 cited
  4. Phase 4 Measles-Rubella Vaccine Immunogenicity at 6 and 9 Months of Age Completed · 3 cited
  5. Phase 4 Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine Completed
  6. Phase 4 Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED) Completed
  7. Phase 3 Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136 Completed
  8. Phase 3 Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers Completed
  9. Phase 3 Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines Completed
  10. Phase 3 V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019) Completed
  11. Phase 3 ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED) Completed
  12. Phase 3 Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers Completed
  13. Phase 3 A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers Completed
  14. Phase 3 Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers Completed
  15. Phase 3 A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014) Completed
  16. Phase 3 Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED) Completed
  17. Phase 3 Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027) Completed
  18. Phase 2 ProQuad Dose Selection Study (V221-011)(COMPLETED) Completed
  19. Phase 2 Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age Completed
  20. Phase 2 Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds Completed
  21. Phase 2 Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age Completed

Showing the 27 most-cited and recently-updated of 27 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Rubella: what the trials found

Multiple vaccine formulations have demonstrated high efficacy in inducing rubella seropositivity. The MR vaccine showed 94% seropositivity at 6 months and 99-100% at 9 months 1. A live attenuated Japanese Encephalitis vaccine also demonstrated approximately 99.7-100% rubella seropositivity 56 days post-vaccination 2. Additionally, a chimeric virus vaccine (JECV) combined with MMR showed seroconversion rates of 97.6% to 100% 14.

Several combination vaccines provide robust rubella immunity. Priorix demonstrated rubella antibody concentrations above the cut-off in 97.1-99.7% of subjects [6, 8] and successfully induced seroconversion for rubella antibodies 13. ProQuad showed high rates of meeting antibody response criteria for rubella (up to 100%) at both four and six weeks post-treatment 10, with overall multi-pathogen response rates reaching up to 99.1% 9.

For the clinician treating this condition

  • Multiple vaccine platforms, including MR, Priorix, and ProQuad, consistently demonstrate high rubella seropositivity or antibody concentrations above clinical cut-offs.
  • Combination vaccines (e.g., MMRV, ProQuad) are effective at inducing rubella immunity alongside other pathogens like measles, mumps, and varicella.

AI synthesis of 6 cited trials, updated Jun 28, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
GSK investigational MMRV vaccine shows comparable immunogenicity to licensed MMRV in healthy children
Pediatrics RCT
GSK investigational MMRV vaccine shows comparable immunogenicity to licensed MMRV in healthy children GSK MMRV vaccine shows comparable safety and immune response to licensed MMRV in young children
This randomized, multi-country phase II trial in 801 healthy children aged 4-6 years found that one dose of a GSK investigational MMRV vacci…
A Phase II trial in healthy children found the investigational GSK MMRV vaccine produced immune responses and safety similar to the licensed…
May 27, 2026
WHO European Region reports rubella incidence trends from 2005 to 2019
Infectious Disease
WHO European Region reports rubella incidence trends from 2005 to 2019 What happened to rubella in Europe over 15 years?
An observational WHO report describes rubella incidence patterns across European regions from 2005 to 2019.
A new report tracks rubella cases across Europe from 2005 to 2019, but it does not share the actual findings or specific trends for the regi…
CDC Apr 6, 2026
Report summarizes global progress toward rubella and congenital rubella syndrome elimination
Infectious Disease
Report summarizes global progress toward rubella and congenital rubella syndrome elimination How close are we to wiping out rubella and its devastating birth defects?
A summary report describes global progress toward eliminating rubella and congenital rubella syndrome from 2012 to 2022.
Global health experts are tracking progress to wipe out rubella and prevent devastating birth defects like deafness and blindness in babies.
CDC Apr 5, 2026
Field report describes congenital rubella syndrome cases in Florida
Infectious Disease
Field report describes congenital rubella syndrome cases in Florida Florida health officials report cases of congenital rubella syndrome
A field report describes cases of congenital rubella syndrome in Florida.
Florida health officials confirm cases of congenital rubella syndrome, a rare condition causing serious birth defects, highlighting the impo…
CDC Apr 4, 2026
PRIORIX vaccine recommended for measles, mumps, and rubella protection in the United States
Allergy & Immunology
PRIORIX vaccine recommended for measles, mumps, and rubella protection in the United States CDC panel recommends PRIORIX vaccine for measles, mumps, and rubella protection
A recommendation for the use of PRIORIX vaccination against measles, mumps, and rubella has been issued in the United States.
A CDC advisory panel now recommends the PRIORIX vaccine as a new option alongside the familiar MMR shot for measles, mumps, and rubella prot…
CDC Apr 4, 2026
Global rubella vaccine coverage reaches 87% of countries, but elimination achieved in only 42%
Pediatrics
Global rubella vaccine coverage reaches 87% of countries, but elimination achieved in only 42% How close are we to wiping out rubella worldwide?
A global surveillance report covering 194 countries from 2000-2018 found 168 countries (87%) protect infants with rubella-containing vaccine…
While 168 countries now protect infants with rubella vaccines, only 81 have eliminated the virus entirely, leaving millions still at risk of…
CDC Apr 4, 2026

Questions about Rubella

Is the PRIORIX vaccine recommended for protecting against Rubella in the United States?

Yes, the PRIORIX vaccine is recommended in the United States for protection against rubella, along with measles and mumps.

Full answer →